A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Inclusion Criteria: Healthy adults * Male or female * Non-smoker * 18-55 years old * BMI \> 18.5 and \< 30.0 * With medically acceptable form of contraception (female only). Exclusion Criteria: * Any clinically significant abnormality or vital sign abnormalities * Any abnormal laboratory test * History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests * Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication * Positive pregnancy test, breastfeeding or lactating * Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors * Participation in an investigational study within 30 days prior to dosing * Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of \> 499 mL (within 56 days) prior to dosing.